Portal de Periódicos da CAPES

A novel isoflavone, ME-344, targets the cytoskeleton in acute myeloid leukemia

2016; Impact Journals LLC; Volume: 7; Issue: 31 Linguagem: Inglês

10.18632/oncotarget.10446

1949-2553

Danny V. Jeyaraju, Rose Hurren, Xiaoming Wang, Neil MacLean, Marcela Gronda, Aisha Shamas‐Din, Mark D. Minden, Guri Giaever, Aaron D. Schimmer,

Cancer therapeutics and mechanisms

The isoflavone ME-344 is a potent anti-cancer agent with preclinical and clinical efficacy in solid tumors. Yet, the mechanism of action of ME-344 has not been fully defined and the preclinical efficacy in leukemia has not been established. Therefore, we investigated the anti-leukemic properties and mechanism of action of ME-344. In a panel of 7 leukemia cell lines, ME-344 was cytotoxic with an IC50 in the range of 70-260 nM. In addition, ME-344 was cytotoxic to primary AML patient samples over normal hematopoietic cells. In an OCI-AML2 xenograft model, ME-344 reduced tumor growth by up to 95% of control without evidence of toxicity. Mechanistically, ME-344 increased mitochondrial ROS generation in leukemic cells. However, antioxidant treatment did not rescue cell death, suggesting that ME-344 had additional targets beyond the mitochondria. We demonstrated that ME-344 inhibited tubulin polymerization by interacting with tubulin near the colchicine-binding site. Furthermore, inhibition of tubulin polymerization was functionally important for ME-344 induced death. Finally, we showed that ME-344 synergizes with vinblastine in leukemia cells. Thus, our study demonstrates that ME-344 displays preclinical efficacy in leukemia through a mechanism at least partly related to targeting tubulin polymerization.